ATE478945T1 - Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten - Google Patents

Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Info

Publication number
ATE478945T1
ATE478945T1 AT06019642T AT06019642T ATE478945T1 AT E478945 T1 ATE478945 T1 AT E478945T1 AT 06019642 T AT06019642 T AT 06019642T AT 06019642 T AT06019642 T AT 06019642T AT E478945 T1 ATE478945 T1 AT E478945T1
Authority
AT
Austria
Prior art keywords
virus
concentration
methods
containing compositions
preparations
Prior art date
Application number
AT06019642T
Other languages
English (en)
Inventor
Andreas Frei
Henry K H Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Laureano L Bondoc
Frederick William Porter
John Chu-Tay Tang
Peter Ihnat
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE478945T1 publication Critical patent/ATE478945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06019642T 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten ATE478945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ATE478945T1 true ATE478945T1 (de) 2010-09-15

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06019642T ATE478945T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
AT04030395T ATE371020T1 (de) 1998-02-17 1999-02-12 Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
AT99906690T ATE341614T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04030395T ATE371020T1 (de) 1998-02-17 1999-02-12 Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
AT99906690T ATE341614T1 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Country Status (24)

Country Link
EP (4) EP1054955B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100862169B1 (de)
CN (2) CN101164623B (de)
AR (3) AR020054A1 (de)
AT (3) ATE478945T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2723040A1 (de)
CO (1) CO4820440A1 (de)
DE (3) DE69936948T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2290613T3 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275781A1 (en) 2004-11-03 2006-12-07 Introgen Therapeutics Inc. Novel method for the protection and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
ES2323991T3 (es) * 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A1 (en) * 2000-12-12 2002-06-24 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
BR0306925A (pt) * 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CN101208425B (zh) 2004-12-13 2011-01-26 坎吉有限公司 产生复制缺陷型腺病毒的细胞系
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
DK2007883T3 (da) * 2006-04-20 2012-02-06 Wyeth Llc Rensningsfremgangsmåder til isolering af renset vesikulær stomatitis-virus fra cellekultur
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
EP2536829B1 (de) 2010-02-15 2016-04-06 Crucell Holland B.V. Verfahren zur Herstellung von adenoviralen Ad26-Vektoren
EP2618838A1 (de) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutische impfung gegen aktive tuberkulose
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
ES2822199T3 (es) * 2011-04-29 2021-04-29 Oncolytics Biotech Inc Métodos de purificación de virus usando cromatografía por permeación en gel
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN110590916A (zh) 2013-04-25 2019-12-20 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
KR20170004966A (ko) * 2014-05-28 2017-01-11 에이전시 포 사이언스, 테크놀로지 앤드 리서치 바이러스 감소 방법
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
JP7539420B2 (ja) * 2019-06-28 2024-08-23 武田薬品工業株式会社 アデノ随伴ウイルスの精製方法
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112022018615A2 (pt) * 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
KR100918187B1 (ko) 2009-09-22
ATE341614T1 (de) 2006-10-15
AR020054A1 (es) 2002-04-10
EP1526174A2 (de) 2005-04-27
PE20000265A1 (es) 2000-04-25
HU226015B1 (en) 2008-02-28
EP1526173A3 (de) 2005-08-10
CN1297478A (zh) 2001-05-30
IL137510A (en) 2012-10-31
BR9908015A (pt) 2001-04-24
EP1054955A2 (de) 2000-11-29
EP1741777A1 (de) 2007-01-10
CN100374551C (zh) 2008-03-12
MY141641A (en) 2010-05-31
ES2290613T3 (es) 2008-02-16
TWI232107B (en) 2005-05-11
DE69942708D1 (de) 2010-10-07
KR20080065615A (ko) 2008-07-14
EP1526173B1 (de) 2012-11-21
CA2320419C (en) 2011-02-08
KR20090038927A (ko) 2009-04-21
CO4820440A1 (es) 1999-07-28
PT1054955E (pt) 2007-01-31
ES2272053T3 (es) 2007-04-16
PL342847A1 (en) 2001-07-16
NO20004104D0 (no) 2000-08-16
HUP0100670A3 (en) 2003-10-28
ATE371020T1 (de) 2007-09-15
DE69936948T2 (de) 2008-05-15
SK11842000A3 (sk) 2001-05-10
AR063315A2 (es) 2009-01-21
WO1999041416A3 (en) 1999-11-18
DK1054955T3 (da) 2007-01-15
AU757976B2 (en) 2003-03-13
AR063314A2 (es) 2009-01-21
DE69933433T2 (de) 2007-08-23
JP2010213727A (ja) 2010-09-30
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
EP1054955B1 (de) 2006-10-04
EP1526174A3 (de) 2005-08-31
HUP0100670A2 (hu) 2001-06-28
PL197747B1 (pl) 2008-04-30
KR100912362B1 (ko) 2009-08-19
IL137510A0 (en) 2001-07-24
CA2723040A1 (en) 1999-08-19
KR20080065614A (ko) 2008-07-14
EP1526174B1 (de) 2007-08-22
CA2320419A1 (en) 1999-08-19
DE69936948D1 (de) 2007-10-04
JP4358434B2 (ja) 2009-11-04
ID28298A (id) 2001-05-10
EP1741777B1 (de) 2010-08-25
HK1073481A1 (en) 2005-10-07
KR20010072547A (ko) 2001-07-31
KR20090127947A (ko) 2009-12-14
KR100991683B1 (ko) 2010-11-04
WO1999041416A2 (en) 1999-08-19
AU2653899A (en) 1999-08-30
HK1097413A1 (en) 2007-06-22
DE69933433D1 (de) 2006-11-16
KR101018992B1 (ko) 2011-03-07
NO20004104L (no) 2000-10-17
CN101164623B (zh) 2012-11-14
JP2002503484A (ja) 2002-02-05
CN101164623A (zh) 2008-04-23
EP1526173A2 (de) 2005-04-27
KR100862169B1 (ko) 2008-10-09

Similar Documents

Publication Publication Date Title
ATE341614T1 (de) Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
EP1303299A4 (de) Zusammensetzungen und methoden zur verstärkung der immunogenität von antigenen
EP1254267A4 (de) Zusammensetzungen und methoden zur früherkennung von eierstockkrebs
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69837703D1 (de) Methoden zum nachweis und zur analyse von virus
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
ATE478138T1 (de) Verfahren zur inaktivierung von lipidumhüllten viren
EP1324780A4 (de) Methoden zur behandlung von herzarrhythmie
DE69921853D1 (de) Vorrichtung zur behandlung von abgas
EP1328284A4 (de) Neue medizinische kräuterzusammensetzung zur behandlung von lebererkrankungen und hiv
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE69822473D1 (de) Lipid-polyamid-konjugate und zusammensetzungen zur verabreichung von nucleinsäuremolekülen
EP1052988A4 (de) Methoden und zusammenstellungen zur inaktivierung von viren
EP0569703A3 (de) Verfahren zur Behandlung und Verhütung viraler Infektionen unter Verwendung von HBNF und MK Protein.
EP1162934A4 (de) Zusammensetzungen und vefahren zur vorbeugung von lichtalterung
DE69935326D1 (de) Zusammensetzungen enthaltend molybden zur steigerung des proteinanabolismus und der entgiftung
DE69933121D1 (de) Methode, reagent und testsatz zur typisierung des genoms von papillomavirus
DE60222233D1 (de) Prozessor und Verfahren zur Erhaltung der Verarbeitungsreihenfolge von Paketen basierend auf Paketstromkennungen
DE69631443D1 (de) Reagens zur untersuchung von viren-agglutination und kit zur untersuchung auf viren
ATE211928T1 (de) Verfahren zur inaktivierung von viren in proteinen
DE60200713D1 (de) Zusammensetzung enthaltend getrocknetes Vollei zur Behandlung von Hepatitis
DE59905059D1 (de) Verfahren zur Herstellung von Hydroxyethylcyclohexanen und Hydroxyethylpiperidinen
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties